녹내장 치료제 시장(2026-2036년) : 질환 현황, 개발 파이프라인, 규제 동향 및 예측

The “Glaucoma Drugs Market 2026 to 2036: Disease Landscape, Pipeline, Regulatory Dynamics and Forecasts” report presents an in-depth assessment of the glaucoma drugs market with forecasts from 2026 to 2036 and historical data from 2021. It covers disease biology and key application areas, approved therapies and generic dynamics, the R&D pipeline, regulatory and reimbursement frameworks across major markets, delivery route innovation, the future roadmap, value chain analysis, competitive dynamics, and strategic recommendations for market participants. The report additionally includes profiles and strategies of leading glaucoma drug developers.

Market size forecasts are segmented across 7 indications, 6 drug classes, 3 distribution channels, branded and generic supply, 5 regional markets, and 26 country markets. The pipeline analysis covers 53 active clinical and preclinical programs across seven mechanistic classes.

The report is accompanied by an Excel datasheet suite covering all quantitative forecast data and the full glaucoma drug pipeline dataset.

The Glaucoma Drugs Market 2026 to 2036: Disease Landscape, Pipeline, Regulatory Dynamics and Forecasts

Synopsis: Glaucoma is a group of progressive optic neuropathies and the leading cause of irreversible blindness worldwide. Damage to the optic nerve produces permanent loss of peripheral and ultimately central vision. Elevated intraocular pressure is the principal modifiable risk factor, yet a substantial portion of patients experience optic nerve damage despite normal-range pressures. Because vision already lost cannot be recovered, treatment is directed at slowing progression rather than restoring function.

Drug therapy remains the first-line intervention across most glaucoma indications, ahead of laser treatment and incisional surgery. Topical eye drops have defined the treatment paradigm for four decades, and prostaglandin analogs have anchored first-line therapy since the late 1990s. ROCK inhibitors, sustained-release intracameral implants, and preservative-free fixed-dose combinations have since broadened the format landscape, while neuroprotective and pressure-independent mechanisms are advancing through mid-stage development.

The global glaucoma drugs market is forecast to exceed $10 billion in 2026 and to expand at a mid single-digit CAGR through 2036. Growth is supported by aging populations, rising prevalence across Asia, earlier diagnosis through improved imaging, and the expansion of treatment into normal-tension disease.

The prostaglandin-anchored treatment paradigm is in structural transition. ROCK inhibitors arrived as the first new mechanism class approved for glaucoma in over two decades, sustained-release intracameral implants have moved therapy out of the pharmacy and into the procedure room, and preservative-free fixed-dose combinations are consolidating multi-drop regimens. Genericization across the established base is simultaneously reshaping pricing, formulary dynamics, and originator share.

Normal-tension glaucoma, in which optic nerve damage progresses without elevated pressure, is poorly served by conventional therapy and is now a named indication across several mid-stage programs. Pressure-independent mechanisms including KATP channel modulation and neuroprotection are advancing against that unmet need, alongside delivery platforms addressing the adherence problem in chronic topical therapy.

Delivery platforms account for a substantial share of active development programs, reflecting the central commercial problem in the category, which is poor adherence to chronic topical therapy. Candidates in development span intracameral and intravitreal implants, punctal plugs, drug-eluting contact lenses and intraocular lenses, ocular rings, microdose sprays, and transdermal eyelid delivery.

The“Glaucoma Drugs Market 2026 to 2036: Disease Landscape, Pipeline, Regulatory Dynamics and Forecasts” report presents an in-depth assessment of the glaucoma drugs market with forecasts from 2026 to 2036 and historical data from 2021. It covers disease biology and key application areas, approved therapies and generic dynamics, the R&D pipeline, regulatory and reimbursement frameworks across major markets, delivery route innovation, the future roadmap, value chain analysis, competitive dynamics, and strategic recommendations for market participants. The report additionally includes profiles and strategies of leading glaucoma drug developers.

Market size forecasts are segmented across 7 indications, 6 drug classes, 3 distribution channels, branded and generic supply, 5 regional markets, and 26 country markets. The pipeline analysis covers 53 active clinical and preclinical programs across seven mechanistic classes.

The report is accompanied by an Excel datasheet suite covering all quantitative forecast data and the full glaucoma drug pipeline dataset.

Key Findings:

The report has the following key findings:

• The global glaucoma drugs market is forecast to exceed $10 billion in 2026 and to expand at a mid single-digit CAGR through 2036, supported by aging populations, rising prevalence across Asia, earlier diagnosis through improved imaging, and the extension of treatment into pressure-independent disease.
• The prostaglandin-anchored treatment paradigm is in structural transition. ROCK inhibitors arrived as the first new mechanism class approved for glaucoma in over two decades, following Japan's approval of ripasudil in 2014 and the US approval of netarsudil in 2017, and sepetaprost reached the Japanese market in October 2025 as the most recent novel mechanism to launch.
• Sustained-release intracameral delivery is moving glaucoma therapy out of the pharmacy and into the procedure room. Durysta was approved in 2020 and iDose TR in 2023, and the FDA approval of a repeat-treatment protocol in January 2026 converted a single-administration implant into a re-administrable one. The shift replaces a pharmacy benefit claim with a dual-component drug and procedure claim, which changes both the reimbursement model and the site of care.
• Normal-tension glaucoma, in which optic nerve damage progresses without elevated intraocular pressure, remains poorly served by conventional pressure-lowering therapy. It is now a named indication across several mid-stage programs, and pressure-independent mechanisms including KATP channel modulation are advancing against that unmet need.
• The glaucoma pipeline is entering its most mechanistically diverse period. This report profiles active clinical and preclinical programs spanning prostanoid modulation, ROCK inhibition, adrenergic modulation, KATP channel modulation, nitric oxide donation, neuroprotection, and cell, gene, and RNA therapy.
• Neuroprotection represents the largest concentration of genuinely novel biology in the pipeline and carries the most regulatory uncertainty. Every approved glaucoma drug is indicated on the basis of intraocular pressure reduction, and no functional or structural endpoint has yet supported an approval. Endpoint negotiation rather than mechanism validation is the gating task for this cohort.
• Cell and gene therapy has entered the glaucoma clinic for the first time. ER-100 began Phase 1 dosing in June 2026 in open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, and NT-501 is in Phase 2 for glaucoma-related visual impairment following its 2025 approval in macular telangiectasia.
• Emerging markets across Asia Pacific, Middle East & Africa, and Latin & Central America are projected to grow above the global average, supported by expanding specialist infrastructure, improving reimbursement, and broad generic accessibility.

Topics Covered:

The report covers the following topics:

• Global glaucoma drugs market sizing, segmentation, and forecasts from 2021 to 2036
• Market drivers, barriers, and macro-environmental trends
• Approved drug classes and leading commercial products across all major glaucoma indications
• Development pipeline review across 53 active candidates
• Advanced drug delivery technologies and sustained-release innovation platforms
• Future roadmap for glaucoma drug development to 2036
• Glaucoma drugs value chain analysis
• Company profiles and strategies of leading ecosystem players
• Competitive landscape including acquisitions, alliances, and licensing activity
• Regulatory frameworks and reimbursement mechanisms across the US, EU, UK, Japan, and China
• Generic competition, Paragraph IV litigation, and the patent landscape across established and post-2017 branded agents
• Strategic recommendations for developers, investors, and healthcare stakeholders

Key Questions Answered:

The report provides answers to the following key questions:

• How large is the global glaucoma drugs market in 2026 and how will it evolve through 2036?
• What structural forces are driving market growth and what barriers constrain it?
• How do headline category growth and addressable branded revenue relate to one another, and how should developers and investors reflect that in their models?
• How is genericization reshaping pricing, formulary dynamics, and originator share across established and post-2017 branded agents?
• Which indications, drug classes, delivery formats, and distribution channels will generate the highest growth through 2036?
• Which country and regional markets offer the highest growth potential and what is driving geographic rebalancing?
• Which indications are emerging as distinct commercial opportunities beyond established open-angle disease, and which mechanisms are positioned to serve them?
• What sustained-release and alternative delivery platforms are advancing toward approval, and how will they alter the competitive dynamic and the reimbursement model?
• Who are the leading market participants and what strategies are they pursuing?
• What strategies should drug developers, investors, and healthcare stakeholders adopt to capitalize on market opportunities through 2036?

Forecast Segmentation:

The report provides detailed revenue forecasts across multiple dimensions of the Glaucoma Drugs market, including:

Indication

• Primary Open-Angle Glaucoma (POAG)
• High-Tension POAG
• Normal-Tension Glaucoma (NTG)
• Primary Angle-Closure Glaucoma (PACG)
• Ocular Hypertension (OHT)
• Secondary Glaucoma
• Congenital Glaucoma

Drug Class

• Prostaglandin Analogs
• Beta Blockers
• Alpha Agonists
• Carbonic Anhydrase Inhibitors
• ROCK (Rho Kinase) Inhibitors
• Combinations & Others

Originator vs Generic

• Branded Drugs
• Generic Drugs

Distribution Channel

• Hospital / Specialty Pharmacies
• Retail Pharmacy
• Online Pharmacies / D2C

Regional Markets

• Asia Pacific
• Europe
• Middle East & Africa
• North America
• Latin & Central America

Country Markets

• Australia
• Brazil
• Canada
• China
• Egypt
• France
• Germany
• Greece
• India
• Israel
• Italy
• Japan
• Mexico
• Netherlands
• Poland
• Portugal
• Russia
• Saudi Arabia
• South Africa
• South Korea
• Spain
• Switzerland
• Taiwan
• Turkey
• UK
• USA

Table of Contents

Chapter 1: Introduction

• 1.1 Executive Summary
• 1.2 Topics Covered
• 1.3 Forecast Segmentation
• 1.4 Key Questions Answered
• 1.5 Key Findings
• 1.6 Methodology
• 1.7 Target Audience
• 1.8 Companies & Organizations Mentioned
  • 1.8.1 Companies
  • 1.8.2 Regulatory Bodies & Organizations

Chapter 2: An Overview of Glaucoma Drugs

• 2.1 What is Glaucoma?
• 2.2 What Causes Glaucoma?
  • 2.2.1 Excessive IOP (Intraocular Pressure)
  • 2.2.2 How Does Pressure Build Up in the Eye?
  • 2.2.3 NTG (Normal-Tension Glaucoma)
  • 2.2.4 Related Conditions
    • 2.2.4.1 Ocular Hypertension
    • 2.2.4.2 Glaucoma Suspects
• 2.3 Types of Glaucoma
  • 2.3.1 Open-Angle Glaucoma
  • 2.3.2 Angle-Closure Glaucoma
  • 2.3.3 Secondary Glaucoma
  • 2.3.4 Congenital Glaucoma
  • 2.3.5 Iridocorneal Endothelial (ICE) Syndrome
• 2.4 The Role of Drugs in Glaucoma Treatment
  • 2.4.1 Eye Drops
  • 2.4.2 Injections
  • 2.4.3 Oral Pills
• 2.5 Other Treatment Options
  • 2.5.1 Laser Treatment
  • 2.5.2 Surgery
  • 2.5.3 MIGS
• 2.6 Market Growth Drivers
  • 2.6.1 Impact of Glaucoma on Daily Life
  • 2.6.2 Growing Prevalence of Glaucoma
  • 2.6.3 Longevity on the Rise
  • 2.6.4 Advances in Drug Delivery Technologies
  • 2.6.5 Other Factors
• 2.7 Market Barriers
  • 2.7.1 Patient Compliance & Lack of Awareness
  • 2.7.2 Alternative Healing Options
  • 2.7.3 Innovator vs. Generic Disputes
  • 2.7.4 Lack of Healthcare Insurance
  • 2.7.5 Preservative-Related Ocular Surface Disease

Chapter 3: Drug Class Availability & Leading Therapies

• 3.1 Drug Class Availability
  • 3.1.1 Prostaglandin Analogs
  • 3.1.2 Beta Blockers
  • 3.1.3 Alpha Agonists
  • 3.1.4 Carbonic Anhydrase Inhibitors
  • 3.1.5 ROCK (Rho Kinase) Inhibitors
  • 3.1.6 Combinations & Others
• 3.2 Leading Glaucoma Drugs
  • 3.2.1 Prostaglandin Analogs
    • 3.2.1.1 Bimatoprost
    • 3.2.1.2 Catioprost
    • 3.2.1.3 Latanoprost
    • 3.2.1.4 Latanoprost Preservative-Free Solution
    • 3.2.1.5 Latanoprost Cationic Emulsion
    • 3.2.1.6 Latanoprostene Bunod
    • 3.2.1.7 Omidenepag Isopropyl
    • 3.2.1.8 Sepetaprost
    • 3.2.1.9 Tafluprost
    • 3.2.1.10 Travoprost
    • 3.2.1.11 Unoprostone Isopropyl
  • 3.2.2 Beta Blockers
    • 3.2.2.1 Betaxolol
    • 3.2.2.2 Carteolol
    • 3.2.2.3 Levobunolol
    • 3.2.2.4 Metipranolol
    • 3.2.2.5 Timolol
  • 3.2.3 Alpha Agonists
    • 3.2.3.1 Apraclonidine
    • 3.2.3.2 Brimonidine
  • 3.2.4 Carbonic Anhydrase Inhibitors
    • 3.2.4.1 Acetazolamide
    • 3.2.4.2 Brinzolamide
    • 3.2.4.3 Dorzolamide
    • 3.2.4.4 Methazolamide
  • 3.2.5 ROCK Inhibitors
    • 3.2.5.1 Netarsudil
    • 3.2.5.2 Netarsudil and Latanoprost
    • 3.2.5.3 Ripasudil
  • 3.2.6 Intracameral Sustained-Release Implants
    • 3.2.6.1 Bimatoprost Intracameral Implant
    • 3.2.6.2 Travoprost Intracameral Implant
  • 3.2.7 Fixed-Dose Combinations
    • 3.2.7.1 Brinzolamide and Brimonidine
    • 3.2.7.2 Brimonidine and Timolol
    • 3.2.7.3 Dorzolamide and Timolol
  • 3.2.8 Other and Adjunctive Agents
    • 3.2.8.1 Aflibercept
    • 3.2.8.2 Bevacizumab
    • 3.2.8.3 Carbachol
    • 3.2.8.4 Dipivefrin
    • 3.2.8.5 Pilocarpine
• 3.3 The Patent Cliff and Generic Competition

Chapter 4: R&D Pipeline and Prospects of New Therapies

• 4.1 Key Areas of New Drug Development
• 4.2 Review of Key Glaucoma Pipeline Candidates
  • 4.2.1 Adrenergic Modulators
  • 4.2.2 Cell, Gene, and RNA Therapies
  • 4.2.3 KATP Channel Modulators
  • 4.2.4 Neuroprotective and Emerging Mechanisms
  • 4.2.5 Nitric Oxide Donors
  • 4.2.6 Prostanoid Modulators
  • 4.2.7 ROCK Inhibitors
  • 4.2.8 Compliance Imperative: Why Delivery Innovation Dominates Investment
  • 4.2.9 Near-Term Approval Horizon: What Reaches Market Before

Chapter 5: Glaucoma Drugs Future Roadmap & Value Chain

• 5.1 Future Roadmap
  • 5.1.1 Pre-2030: Consolidation, Combination Therapies & Emerging Novel Drug Classes
  • 5.1.2 2030 - 2033: Maturation of Biologics, Gene Therapies & Disease-Modifying Approaches
  • 5.1.3 2033 - 2036 & Beyond: SR Delivery, Digital Integration & Personalized Glaucoma Management
  • 5.1.4 Roadmap Outlook
• 5.2 Value Chain
  • 5.2.1 API Manufacturers & Enabling Technology Providers
  • 5.2.2 Generic Drug Manufacturers
  • 5.2.3 Innovator Pharmaceutical Companies
  • 5.2.4 Regional Distributors
  • 5.2.5 Healthcare Providers, Pharmacies & Drug Stores

Chapter 6: Glaucoma Drugs Regulatory Landscape

• 6.1 United States: FDA Regulatory Pathways
  • 6.1.1 Primary Approval Pathways
  • 6.1.2 Expedited Development Programs
  • 6.1.3 Manufacturing and CMC Risk
  • 6.1.4 Reimbursement: Centers for Medicare and Medicaid Services
• 6.2 European Union and United Kingdom
  • 6.2.1 United Kingdom: MHRA and the Relaunched ILAP
  • 6.2.2 HTA and Reimbursement: European Frameworks
• 6.3 Japan: PMDA, Sakigake, and Annual Price Revision
• 6.4 China: NMPA, NRDL, and Volume-Based Procurement
• 6.5 Generic Drug Regulatory Frameworks
  • 6.5.1 United States: ANDA and Paragraph IV
  • 6.5.2 European Generic and Parallel Import Frameworks
  • 6.5.3 China: Generic Framework and Procurement
  • 6.5.4 Japan: Generic Substitution Framework
  • 6.5.5 Rest of World Generic and Regional Frameworks
• 6.6 Regulatory Designation Profiles of Late-Stage Programs
• 6.7 The Neuroprotection Endpoint Problem
• 6.8 Regulatory Landscape: Commercial Implications

Chapter 7: Key Market Players

• 7.1 AbbVie Inc.
• 7.2 Alcon Inc.
• 7.3 Allysta Pharmaceuticals
• 7.4 Amorphex Therapeutics
• 7.5 Astellas Pharma
• 7.6 Bausch + Lomb
• 7.7 Bayer AG
• 7.8 Betaliq
• 7.9 BioAxone Biosciences
• 7.10 BioLight Life Sciences Ltd.
• 7.11 Accure Therapeutics
• 7.12 D.Western Therapeutics Institute Inc.
• 7.13 Optus Pharmaceuticals Co., Ltd.
• 7.14 Dompe Farmaceutici
• 7.15 PulseSight Therapeutics SAS
• 7.16 Fera Pharmaceuticals LLC
• 7.17 Fidia Farmaceutici S.p.A.
• 7.18 Glaukos Corporation
• 7.19 HitGen Inc.
• 7.20 ID Pharma Co.
• 7.21 InMed Pharmaceuticals
• 7.22 Isarna Therapeutics
• 7.23 Kowa Company
• 7.24 Laboratorios SALVAT S.A.
• 7.25 Laboratorios Sophia
• 7.26 Life Biosciences
• 7.27 Mannin Research
• 7.28 Mati Therapeutics Inc.
• 7.29 MediPrint Ophthalmics
• 7.30 MimeTech S.r.l.
• 7.31 Mundipharma International Limited
• 7.32 Neurotech Pharmaceuticals Inc.
• 7.33 Nicox
• 7.34 Novaliq GmbH
• 7.35 Novartis
• 7.36 Ocular Therapeutix Inc.
• 7.37 Oculis Holding AG
• 7.38 Nanogenics
• 7.39 Oncolys BioPharma Inc.
• 7.40 ONO Pharmaceutical
• 7.41 Opus Genetics
• 7.42 Otero Therapeutics
• 7.43 Otsuka Pharmaceutical Co.
• 7.44 Peregrine Ophthalmic
• 7.45 Perfuse Therapeutics Inc.
• 7.46 Pfizer Inc.
• 7.47 pH Pharma Co
• 7.48 PolyActiva
• 7.49 Q BioMed Inc.
• 7.50 Qlaris Bio Inc.
• 7.51 Radikal Therapeutics
• 7.52 Regeneron Pharmaceuticals Inc.
• 7.53 Replenish Inc.
• 7.54 Roche Holding (F. Hoffmann-La Roche)
• 7.55 Santen Pharmaceutical Company
• 7.56 Senju Pharmaceutical Company
• 7.57 SPARC (Sun Pharma Advanced Research Company)
• 7.58 Taejoon Pharm
• 7.59 Laboratories THEA
• 7.60 TikoMed
• 7.61 UBE Corporation
• 7.62 Wakamoto Company

Chapter 8: Market Sizing & Forecasts

• 8.1 Global Outlook for Glaucoma Drugs
• 8.2 Segmentation by Drug Class
  • 8.2.1 Prostaglandin Analogs
  • 8.2.2 Beta Blockers
  • 8.2.3 Alpha Agonists
  • 8.2.4 Carbonic Anhydrase Inhibitors
  • 8.2.5 ROCK Inhibitors
  • 8.2.6 Combinations & Others
• 8.3 Segmentation by Indication
  • 8.3.1 Primary Open-Angle Glaucoma (POAG)
    • 8.3.1.1 High-Tension POAG
    • 8.3.1.2 Normal-Tension Glaucoma (NTG)
  • 8.3.2 Primary Angle-Closure Glaucoma (PACG)
  • 8.3.3 Ocular Hypertension (OHT)
  • 8.3.4 Secondary Glaucoma
  • 8.3.5 Congenital Glaucoma
• 8.4 Segmentation by Distribution Channel
  • 8.4.1 Hospital / Specialty Pharmacies
  • 8.4.2 Retail Pharmacy
  • 8.4.3 Online Pharmacies / D2C
• 8.5 Segmentation by Originator vs Generic Drugs
  • 8.5.1 Branded Drugs
  • 8.5.2 Generic Drugs
• 8.6 Segmentation by Region
  • 8.6.1 Asia Pacific
  • 8.6.2 Europe
  • 8.6.3 Middle East & Africa
  • 8.6.4 Latin & Central America
  • 8.6.5 North America
• 8.7 Top Country Markets
  • 8.7.1 Australia
  • 8.7.2 Brazil
  • 8.7.3 Canada
  • 8.7.4 China
  • 8.7.5 Egypt
  • 8.7.6 France
  • 8.7.7 Germany
  • 8.7.8 Greece
  • 8.7.9 India
  • 8.7.10 Israel
  • 8.7.11 Italy
  • 8.7.12 Japan
  • 8.7.13 Mexico
  • 8.7.14 Netherlands
  • 8.7.15 Poland
  • 8.7.16 Portugal
  • 8.7.17 Russia
  • 8.7.18 Saudi Arabia
  • 8.7.19 South Africa
  • 8.7.20 South Korea
  • 8.7.21 Spain
  • 8.7.22 Switzerland
  • 8.7.23 Taiwan
  • 8.7.24 Turkey
  • 8.7.25 UK
  • 8.7.26 USA
  • 8.7.27 Rest of the World (RoW)
• 8.8 Commercial Implications for Originator Strategy

Chapter 9: Conclusion & Strategic Recommendations

• 9.1 Why is the Market Poised to Grow?
• 9.2 Competitive Industry Landscape: Acquisitions, Alliances & Consolidation
  • 9.2.1 Corporate Consolidation, 2019 - 2022
  • 9.2.2 Transactions Reshaping the Portfolio, 2024 - 2026
  • 9.2.3 Consolidated Competitive Positioning
• 9.3 Approved Drug Precedents Reshaping the Treatment Paradigm
• 9.4 R&D Pipeline Review: Prospects of New Therapies
  • 9.4.1 Sustained-Release Delivery
  • 9.4.2 ROCK Inhibitors
  • 9.4.3 Prostaglandin Receptor Agonists
  • 9.4.4 Nitric Oxide Donors
  • 9.4.5 KATP Channel Modulators
  • 9.4.6 Adenosine Receptor Modulators
  • 9.4.7 Cell, Gene, and RNA Therapies
  • 9.4.8 Recent Discontinuations and What They Signal
• 9.5 The Patent Cliff and Generic Competition
  • 9.5.1 Patent Expiration and Generic Entry
  • 9.5.2 Regulatory and Reimbursement Dynamics Supporting Commercial Durability
• 9.6 MIGS and the Procedural Competitive Threat
• 9.7 Combination Therapy Products
• 9.8 IOP-Independent and Neuroprotective Therapy
• 9.9 Improving Patient Compliance
  • 9.9.1 The Persistence of Treatment Discontinuation
  • 9.9.2 Reducing Preservative Exposure
  • 9.9.3 Fixed-Dose Combinations and Procedural Delivery
• 9.10 New Formulations & Delivery Routes
  • 9.10.1 Intracameral Implants
  • 9.10.2 Intraocular Lens Combination Platforms
  • 9.10.3 Ocular Surface Platforms
  • 9.10.4 Punctal Plug Delivery
  • 9.10.5 Injectable Posterior-Segment Routes: Intravitreal and Suprachoroidal
  • 9.10.6 Topical Platform and Formulation Innovation
  • 9.10.7 Oral and Nanotechnology-Based Approaches
• 9.11 Geographic Outlook: Which Countries Offer the Highest Growth Potential?
• 9.12 Which Drug Class Leads the Market?
• 9.13 Strategic Recommendations
• 9.14 Which Originators Outperform the Base Case?